Method for treating growth hormone deficiency employing hGH fusion protein
US12427186B2 · kind B2 · utility
0Cited by
3References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 30, 2017 |
| Grant date | Sep 30, 2025 |
| Priority date | — |
| Expiry date | Sep 9, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/61
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating growth hormone deficiency, including administering a human growth hormone fusion protein (GX-H9). A method includes administering a pharmaceutical composition containing an hGH fusion protein (GX-H9) and a pharmaceutically acceptable carrier, wherein the fusion protein (GX-H9) is administered once a week at a dose of 0.4 to 1.6 mg per body weight kg of a pediatric patient, or administered once every two weeks at a dose of 0.8 to 3.2 mg per body weight kg of a pediatric patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.